New diabetes clinical trial: Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome

Published on: March 02, 2023 at 11:00AM
Conditions:   Neurodevelopmental Disorders;   Intellectual Disability;   Development Delay;   ADHD;   Autism Spectrum Disorder;   Epilepsy
Intervention:   Drug: Sulfonylurea
Sponsors:   Royal Devon and Exeter NHS Foundation Trust;   University of Chicago;   University of Bergen;   University of Rome Tor Vergata
Recruiting
https://ift.tt/6XS4gxj